尼洛替尼对伊马替尼耐药CML患者慢性期和加速期疗效分析  

Efficacy of nilotinib for chronic myeloid leukemia in chronic phase and accelerated phase

作　　者：康娅 刘华胜[1] 张梅[1] 

机构地区：[1]西安交通大学医学院第一附属医院血液内科,陕西西安710061

出　　处：《国外医学（医学地理分册）》2014年第2期164-166,共3页Foreign Medical Sciences：Section of Medgeography

基　　金：陕西省科学技术研究发展计划项目(No.2011K13-01-11);西安交通大学医学院第一附属医院院基金(No.2010YK31)

摘　　要：目的：研究尼洛替尼对伊马替尼耐药慢性粒细胞白血病慢性期和加速期的临床疗效及不良反应。方法选择CML慢性期患者12例，加速期患者11例，采用尼洛替尼治疗后分别对疗效、LDH 及a-HBDH及安全性进行评估。结果12例慢性期患者6例获得CHR ，获得缓解的中位数时间为35 d；加速期11名患者中3例获得CHR ，获得缓解的中位数时间为41 d。慢性期患者治疗后LDH 及a-HBDH较治疗前显著下降（P＜0．05），加速期患者经治疗后LDH 及a-HBDH较治疗前显著下降（P＜0．05）。慢性期及加速期患者治疗期间血液系统不良反应主要体现在Ⅲ～Ⅳ级PL T、WBC、HB下降，非血液系统并发症主要体现在发热、皮疹及胃肠道反应。结论尼洛替尼治疗伊马替尼耐药CM L患者具有较好的缓解率且不良反应多可耐受。Objective To study the clinical efficacy of nilotinib for chronic myeloid leukemia （CML） in chron-ic phase and accelerated phase .Methods A total of 12 patients with CML in chronic phase ,and 11 patients in ac-celerated phase were enrolled .Clinical efficacy ,LDH ,a-HBDH ,and safety was assessed after nilotinib therapy . Results Altogether 6 of the 12 chronic cases obtained CHR ,the median remission time being 35 d;3 of the 11 ca-ses in accelerated phase obtained CHR ,the median remission time being 41d .LDH and a-HBDH decreased signifi-cantly in all patients （ P〈0 .05） .The adverse reactions were mainly PLT ,WBC and HB decline in grade Ⅲ-Ⅳ ,fe-ver ,rash and gastrointestinal reactions .Conclusion Imatinib-resistant CML patients showed effective response to nilotinib and could tolerate adverse reactions .

关 键 词：尼洛替尼 慢性粒细胞白血病 慢性期 加速期 

分 类 号：R733[医药卫生—肿瘤]